CCR5 and neoplasm: Finally, a promising therapeutic target in diabetic retinopathy is another dual inhibitor of CCR2/CCR5 named as TAK-779, a quaternary ammonium derivative that reduced retinal vascular leakage in an animal model and Treg infiltration and tumor growth in a pancreatic cancer mouse model [68].